{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:28:51Z","timestamp":1788265731033,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["FOU 2018\u20102019"],"award-info":[{"award-number":["FOU 2018\u20102019"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec><jats:title>Background and objective<\/jats:title><jats:p>Routine antenatal anti\u2010D prophylaxis (RAADP) to RhD\u2010negative women is most often administered in gestational age (GA) 28\u201330\u00a0weeks with the next anti\u2010D dose administered postpartum. The aim of this study was to analyse the proportion of RhD\u2010negative women where RAADP is not detectable at term and in a pilot study to investigate whether RAADP administered in GA 28 and 38 results in detectable levels at term, post\u2010term and post\u2010delivery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>In a retrospective analysis, 4280 RhD\u2010negative women carrying an<jats:italic>RHD<\/jats:italic>positive fetus were included and the proportion with a negative antibody screen at delivery was determined. In the second part, 39 pregnancies were included prospectively, a second dose of RAADP was administered in GA 38\u00a0weeks, and anti\u2010D was quantified before the second dose and then weekly for 5\u00a0weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the retrospective analysis, 20\u00b75% (856\/4280) with RAADP administered in GA 28 were negative in routine antibody screening at delivery. In the small prospective study, 18% (7\/39) had a negative antibody screen and 26% (10\/39) had levels below 0\u00b7005\u00a0IU\/ml, in the quantification assay, in GA 38. Anti\u2010D prophylaxis administered in GA 38 showed detectable levels of anti\u2010D up to 30\u00a0days post\u2010delivery, with concentration at delivery 0\u00b7060\u00a0\u00b1\u00a00\u00b7034\u00a0IU\/ml (mean\u00a0\u00b1\u00a0SD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Approximately 20% of the RhD\u2010negative women show non\u2010detectable levels of anti\u2010D at term. A second dose of RAADP at GA 38 results in stable concentrations of anti\u2010D at term, post\u2010term and post\u2010delivery, but with large interindividual variation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vox.13092","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T20:14:51Z","timestamp":1616876091000},"page":"1005-1011","source":"Crossref","is-referenced-by-count":8,"title":["Altered strategy of prophylactic anti\u2010D administration in pregnancy to cover term and post\u2010term \u2013 a pilot study"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8810-7974","authenticated-orcid":false,"given":"Agneta","family":"Wikman","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology and Transfusion Medicine Karolinska University Hospital Stockholm Sweden"},{"name":"Division of Immunology Department of CLINTEC Karolinska Institute Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"M\u00f6rtberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Transfusion Medicine Karolinska University Hospital Stockholm Sweden"},{"name":"Division of Immunology Department of CLINTEC Karolinska Institute Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Jalkesten","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Transfusion Medicine Karolinska University Hospital Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Jansson","sequence":"additional","affiliation":[{"name":"Pregnancy Care &amp; Delivery Karolinska University Hospital Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Transfusion Medicine Karolinska University Hospital Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonor","family":"Tiblad","sequence":"additional","affiliation":[{"name":"Center for Fetal Medicine Department of Obstetrics and Gynecology Karolinska University Hospital Stockholm Sweden"},{"name":"Clinical Epidemiology Division Department of Medicine Solna Karolinska Institute Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Ajne","sequence":"additional","affiliation":[{"name":"Pregnancy Care &amp; Delivery Karolinska University Hospital Stockholm Sweden"},{"name":"Division of Obstet &amp; Gynecol Department of CLINTEC Karolinska Institute Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,27]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12265"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000328683"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31817d453c"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1998.tb10286.x"},{"key":"e_1_2_11_6_1","doi-asserted-by":"crossref","unstructured":"McBainRD CrowtherCA MiddletonP.Anti\u2010D administration in pregnancy for preventing rhesus alloimmunization. Cochrane Database Syst Rev. 2015.2015;9:CD000020.","DOI":"10.1002\/14651858.CD000020.pub3"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2018.1461562"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2011.01106.x"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50266"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2008.01984.x"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12091"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1986.tb00226.x"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.12193"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2005.00789.x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta13100"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31825d33d9"},{"key":"e_1_2_11_17_1","unstructured":"Graviditetsimmunisering\u201cPregnancy immunisation\u201d2015.https:\/\/www.sfog.se\/media\/275278\/argrapp74_omsl_inledn_lr_f_r_oinloggade.pdf"},{"key":"e_1_2_11_18_1","unstructured":"https:\/\/www.fass.se\/LIF\/result?userType=0&nplId=20021115000215 20021115000208&query=Rhophylac"},{"key":"e_1_2_11_19_1","unstructured":"The Swedish Pregnancy Register www.medscinet.com\/gr\/engelska.aspx"},{"key":"e_1_2_11_20_1","doi-asserted-by":"crossref","unstructured":"AustinE BatesS deSilvaM et\u00a0al.The estimation of fetomaternal haemorrhage. BCSH Blood transfusion and Haematology Task Forces. Transfus Med1999;9:87\u201392.","DOI":"10.1046\/j.1365-3148.1999.009001087.x"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03536.x"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1990.30490273444.x"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-7963(87)70010-8"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0412.2012.01377.x"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2005.00789.x"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030711"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070984"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13092","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.13092","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T06:07:20Z","timestamp":1698127640000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.13092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,27]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/vox.13092"],"URL":"https:\/\/doi.org\/10.1111\/vox.13092","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,27]]}}}